natgillin/translations-raw huggingface dataset:
ESPRIT: This was a double-blind, multicentre, randomised, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo non- emergent percutaneous coronary intervention (PCI) with stent implantation.
ESPRIT: dvostruko slijepo, multicentrično, randomizirano, placebom kontrolirano ispitivanje paralelnih grupa o sigurnosti i djelotvornosti liječenja eptifibatidom bolesnika predviđenih za ne-hitnu perkutanu koronarnu intervenciju (PCI) s implantacijom stenta.
ESPRIT: This was a double-blind, multicentre, randomised, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo non- emergent percutaneous coronary intervention (PCI) with stent implantation.
ESPRIT: dvostruko slijepo, multicentrično, randomizirano, placebom kontrolirano ispitivanje paralelnih grupa o sigurnosti i djelotvornosti terapije eptifibatidom bolesnika predviđenih za ne-hitnu perkutanu koronarnu intervenciju (PCI) s implantacijom stenta.
ESPRIT: This was a double-blind, multicentre, randomized, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo non- emergent percutaneous coronary intervention (PCI) with stent implantation.
ESPRIT: dvostruko slijepo, multicentrično, randomizirano, placebom kontrolirano ispitivanje paralelnih grupa o sigurnosti i djelotvornosti liječenja eptifibatidom u bolesnika predviđenih za ne- hitnu perkutanu koronarnu intervenciju (PCI) s implantacijom stenta.
ESPRIT: This was a double-blind, multicentre, randomized, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo non- emergent percutaneous coronary intervention (PCI) with stent implantation.
ESPRIT: dvostruko slijepo, multicentrično, randomizirano, placebom kontrolirano ispitivanje paralelnih grupa o sigurnosti i djelotvornosti terapije eptifibatidom u bolesnika predviđenih za ne- hitnu perkutanu koronarnu intervenciju (PCI) s implantacijom stenta.
ESR (mm/h): erythrocyte sedimentation rate (milimetres per hour)
ESR (mm/h): brzina sedimentacije eritrocita (milimetara na sat)
ESRD including on haemodialysis3
bubrežne bolesti uključujući one na hemodijalizi3
Essential amino acids including L-phenylalanine Water for injections.
Esencijalne aminokiseline uključujući L-fenilalanin Voda za injekcije.
essential hypertension in adults
esencijalna hipertenzija u odraslih
Essential Patient Information:
Neophodne informacije za bolesnike:
Essex RM10 7XS United Kingdom or
Essex RM10 7XS Ujedinjeno Kraljevstvo ili
Established and other potentially significant drug interactions
Ustanovljene i druge potencijalno značajne interakcije lijekova
Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6)
Ustanovljena trudnoća, sumnja u trudnoću ili u slučaju kada se trudnoća ne može isključiti (vidjeti dio 4.6)
Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6)
Ustanovljena trudnoća, sumnja u trudnoću ili u slučaju kada se trudnoća ne može isključiti (vidjeti dio 4.6.).
Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6).
Potvrñena trudnoća ili sumnja na trudnoću ili kada trudnoća nije isključena (vidjeti dio 4.6).
Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6).
Ustanovljena trudnoća, sumnja na trudnoću ili u slučaju kada trudnoća nije isključena (vidjeti dio 4.6).
Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6).
Ustanovljene ili sumnje na trudnoću ili u slučaju kada se trudnoća ne može isključiti (vidjeti odjeljak 4.6).
established, but may decrease the
nije utvrđen, ali može smanjiti
Established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
Dokazanom, postojećom ili prethodnom ishemijskom bolesti srca, perifernom arterijskom bolesti i/ili cerebrovaskularnom bolesti u anamnezi.
established, the magnitude of
indinavir:
established, the magnitude of the
opsežnost opaženih
established.
nisu ustanovljene.
established.
Noretindron
established.
ritonavira.
established.
sigurnost.
established.
ustanovljene.
established.
utvrđen.
estazolam or flurazepam - used to help you sleep
estazolam ili flurazepam – koriste se da lakše zaspete
Estimate (SE)
Procjena (SE)
Estimate of the treatment hazard ratio, where <1 indicates a lower risk with letrozole 2.5 mg + lapatinib 1500 mg compared with letrozole 2.5 mg + placebo.
Procjena omjera hazarda liječenja, gdje <1 ukazuje na manji rizik s letrozol 2,5 mg + lapatinib 1500 mg u usporedbi s letrozol 2,5 mg + placebo.
Estimated CrCL (mL/min)
Procijenjeni CrCL (ml/min)
Estimated CrCL (mL/min)*
Procijenjeni CrCl (ml/min)
Estimated difference
Procijenjena razlika
Estimated dose absorbed from Lymphoseek in patients with melanomaa
Procijenjena apsorbirana doza za lijek Lymphoseek u bolesnika s melanomoma
Estimated inhalation time
Predviđeno trajanje inhalacije
Estimated maximum liraglutide concentration was 9.4 nmol/l for a subcutaneous single dose of liraglutide 0.6 mg.
Za jednu supkutanu dozu liraglutida od 0,6 mg procijenjena maksimalna koncentracija liraglutida bila je 9,4 nmol/l.
Estimated median survival
2 procijenjeni medijan preživljenja
Estimated odds ratio
Procijenjeni omjer šansi
Estimated Percent of Subjects Without Relapse
Procijenjeni postotak ispitanika bez relapsa
Estimated progression-free rates at 6 months were 98.4% for the everolimus arm and 83.4% for the placebo arm.
Procijenjene stope bez progresije nakon 6 mjeseci bile su 98,4% za skupinu koja je primala everolimus i 83,4% za placebo skupinu.
Estimated radiation absorbed dose for breast cancer, mGy/MBq
Procijenjena apsorbirana doza zračenja za rak dojke, mGy/MBq
Estimated radiation absorbed dose for melanoma, mGy/MBq
Procijenjena apsorbirana doza zračenja za melanom, mGy/MBq
Estimated Radiation Absorbed Doses From [90Y]-Zevalin
procijenjene apsorbirane doze zračenja od [90Y]-Zevalina
Estimated ratio
Procijenjeni omjer
Estimated treatment effects on BMD were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid.
Procijenjeni učinci liječenje na BMD bili su slični, ali ustroj ispitivanja nije bio dovoljno robustan da bi se mogla utvrditi neinferiorna djelotvornost zoledronatne kiseline.
Estimated using the Kaplan-Meier method.
Procijenjeno Kaplan-Meierovom metodom.
Estimated using the Kaplan-Meier method.
Procijenjeno Kaplan-Meierovom metodom. f.
Estonia/ Eesti Lorenzo Pharma OÜ Koidu str.
Estonija/Eesti Lorenzo Pharma OÜ Koidu str.
Estrada do Rio da Mó , nº 8, 8-A e 8-B Fervença, Terrugem SNT, 2705-906 Portugal
Estrada do Rio da Mó, nº 8, 8-A e 8-B Fervença, Terrugem SNT, 2705-906 Portugal
estradiol 0.035 mg daily + Victrelis
etinilestradiol 0,035 mg na dan +
estradiol and of other
drugih oblika hormonske
Estradiol, the oestrogen in IOA, is identical to the hormone produced by your ovaries during a menstrual cycle.
Estradiol, estrogen u lijeku IOA , identičan je hormonu kojeg stvaraju jajnici tijekom mjesečnog ciklusa.
Estradiol, the oestrogen in Zoely, is identical to the hormone produced by your ovaries during a menstrual cycle.
Estradiol, estrogen u lijeku Zoely, identičan je hormonu kojeg stvaraju jajnici tijekom mjesečnog ciklusa.
ET - 76505 Saue/Harjumaa, ESTONIA Tel: + 372 6 709 006
25-27 Dimostheni Severi, 1080 CY-1080 Nicosia - CYPRUS Τηλ: + 357 22456117
ET-1 concentrations in tissues and plasma are increased in several cardiovascular disorders and connective tissue diseases, including pulmonary arterial hypertension, scleroderma, acute and chronic heart failure, myocardial ischaemia, systemic hypertension and atherosclerosis, suggesting a pathogenic role of ET-1 in these diseases.
Koncentracije ET-1 u tkivima i plazmi su povećane kod nekih kardiovaskularnih poremećaja i bolesti vezivnog tkiva, uključujući plućnu arterijsku hipertenziju, sklerodermiju, akutno i kronično zatajenje srca, ishemiju miokarda, sistemsku hipertenziju i aterosklerozu, što ukazuje na patogenu ulogu ET-1 kod tih bolesti.
Etanercept + Methotrexate (n = 231)
Etanercept + Metotreksat (n = 231)
Etanercept did not elicit dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous administration for 4 or 26 consecutive weeks at a dose (15 mg/kg) that resulted in AUC- based serum drug concentrations that were over 27-fold higher than that obtained in humans at the recommended dose of 25 mg.
Kod etanercepta nije zabilježena toksičnost koja bi ograničavala dozu, kao ni toksičnost prema ciljnim organima prilikom primjene u makaki majmuna u dozi od 15 mg/kg supkutano, dva puta tjedno, tijekom 4 ili 26 uzastopnih tjedana, a pri toj su dozi serumske koncentracije lijeka izmjerene na temelju AUC-a bile više od 27 puta veće od one izmjerene u ljudi prilikom primjene preporučene doze od 25 mg.
Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1.
Etanercept je dimer kimeričkog proteina koji se dobiva genetičkim inženjerstvom - fuzijom ekstracelularne domene receptora-2 ljudskog TNF-a za ligande (TNFR2/p75) s Fc domenom ljudskog IgG1.
Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1.
Etanercept je dimer kimeričkog proteina koji se dobiva genskim inženjerstvom - fuzijom ekstracelularne domene receptora-2 ljudskog TNF za ligande (TNFR2/p75) s Fc domenom ljudskog IgG1.
Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1.
Etanercept je dimer kimeričkog proteina koji se dobiva genskim inženjestvom - fuzijom ekstracelularne domene receptora-2 ljudskog TNF za ligande (TNFR2/p75) s Fc domenom ljudskog IgG1.
Etanercept is produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA) that makes them able to produce etanercept.
Etanercept se proizvodi metodom poznatom pod nazivom „tehnologija rekombinatne DNK“: proizvodi se od stanica koje prime gen (DNK) koji im omogućuje proizvodnju etanercepta.
Etanercept is recommended for use in patients as defined in section 4.1. Patients who “failed to respond to” in the target population is defined by insufficient response (PASI < 50 or PGA less than good), or worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long duration to assess response with at least each of the three major systemic therapies as available.
Preporučena je primjena etanercepta kod bolesnika kako je definirano u dijelu 4.1. Bolesnici koji „nisu pokazali odgovor“ u ciljnoj populaciji definirani su kao oni s nedostatnim odgovorom (PASI < 50 ili PGA manji od dobar) ili pogoršanjem bolesti za vrijeme liječenja, a koji su liječeni adekvatnom dozom tijekom dovoljno dugog razdoblja da se mogao procijeniti odgovor na svaki od 3 glavna raspoloživa sistemska lijeka.
Etanercept may also modulate biologic responses controlled by additional downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or regulated by TNF.
Etanercept također može utjecati na biološku aktivnost kontroliranu dodatnim molekulama koje se uključuju kasnije (npr. citokini, adhezijske molekule ili proteinaze), a koje inducira ili nadzire TNF
Etanercept n = 103 to 105*
Etanercept n = 103 do 105
Etanercept was considered to be non-genotoxic from a battery of in vitro and in vivo studies.
Prema nizu učinjenih in vitro i in vivo ispitivanja smatra se da etanercept nije genotoksičan.
Etanercept was significantly better than placebo in all components of the ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the ACR response criteria, such as morning stiffness.
Etanercept se pokazao znatno uspješnijim od placeba u svim pokazateljima odgovora prema kriterijima ACR kao i prema svim ostalim kriterijima aktivnosti reumatoidnog artritisa koji nisu obuhvaćeni kriterijima ACR, kao npr. jutarnja ukočenost.
ETDRS: Early Treatment Diabetic Retinopathy Study LOCF: Last Observation Carried Forward
ETDRS: Ispitivanje ranog liječenja dijabetičke retinopatije LOCF: Zadnje mjerenje preneseno dalje
ETDRS: Early Treatment Diabetic Retinopathy Study SD: Standard Deviation
ETDRS: (= Early Treatment Diabetic Retinopathy Study): Ispitivanje ranog liječenja dijabetičke retinopatije SD: standardna devijacija
etexilate
eteksilat
Ethanol (96 percent) 159.8 mg/ml.
Etanol (96%) 159,8 mg/ml
Ethanol (96 percent): 159.8 mg.
Etanol (96%) 159,8 mg
Ethanol (96%)
etanol (96%)
Ethanol (96%) 159.8 mg
Etanol (96%) 159,8 mg
Ethanol (96%) 159.8 mg Clear, yellow solution.
Etanol (96%) 159,8 mg Jasno, žuta otopina
Ethanol (96%) 159.8 mg.
Etanol (96%) 159,8 mg
Ethanol (96%) 159.8 mg/ml
Etanol (96%) 159,8 mg/ml
Ethanol (96%) 159.8 mg/ml
Ethanol (96%) 159,8 mg/ml
Ethanol (96%) 159.8 mg/ml.
Etanol (96%) 159,8 mg/ml
Ethanol (96%): 159.8 mg
Etanol (96%) 159,8 mg
Ethanol (96%): 159.8 mg/ml
Etanol (96%) 159,8 mg/ml
Ethanol (96%): 159.8 mg/ml.
Etanol (96%) 159,8 mg/ml
Ethanol (96%): 159.8 mg/ml.
Etanol (96%): 159,8 mg/ml
Ethanol (96%): 159.8 mg/ml.
Etanol (96%): 159,8 mg/ml.
Ethanol (anhydrous) Poloxamer 188 Sodium Chloride Glycofurol
Etanol (bezvodni) Poloksamer 188 Natrijev klorid Glikofurol
Ethanol 150 mg
Etanol 150 mg
Ethanol 150 mg A clear yellow solution.
Etanol 150 mg Bistra žuta otopina.
Ethanol 150 mg.
Etanol 150 mg
Ethanol 150 mg/ml
Etanol 150 mg/ml
Ethanol 96 %
Etanol 96
Ethanol 96 % 156.25 mg.
Etanol 96% 156,25 mg.
Ethanol 99.9% 150 mg Clear, yellow solution
Etanol 99,9 % 150 mg Bistra žuta otopina
Ethanol anhydrous 150 mg
Bezvodni etanol 150 mg
Ethanol anhydrous Poloxamer 188 Glycofurol Meglumine Glycine
Bezvodni etanol Poloxamer 188 Glikofurol Meglumin Glicin
Ethanol anhydrous,Water for injections, Hydrochloric acid, Sodium hydroxide See leaflet for further information
etanol bezvodni, voda za injekcije, kloridna kiselina, natrijev hidroksid Za dodatne informacije vidjeti uputu o lijeku.
Ethanol anhydrous,Water for injections,Hydrochloric acid,Sodium hydroxide See leaflet for further information
etanol bezvodni, voda za injekcije, kloridna kiselina, natrijev hidroksid Za dodatne informacije vidjeti uputu o lijeku.
Ethanol Glycine
Etanol Glicin
Ethanol Poloxamer 188
etanol poloksamer 188
Ethanol Poloxamer 188 Sodium chloride Glycine
etanol poloksamer 188 natrijev klorid glicin
Ethanol, absolute Sodium ascorbate Sodium chloride Water for injections
etanol, apsolutni natrijev askorbat natrijev klorid voda za injekcije
Ethanol, anhydrous (E1510) Propylene glycol (E1520)
etanol, bezvodni (E1510) propilenglikol (E1520)
Ethanol, anhydrous 150 mg For a full list of excipients, see section 6.1.
Etanol, bezvodni 150 mg Potpuni popis pomoćnih tvari vidjeti u dijelu 6.1.
Ethanol, anhydrous 150 mg.
Etanol, bezvodni 150 mg.
Ethanol, anhydrous Poloxamer 188
Bezvodni etanol Poloksamer 188
Ethanol/Abacavir
etanol/abakavir
Ethanol/Abacavir (0.7 g/kg single dose/600mg single dose)
etanol/abakavir (0,7 g/kg jednokratna doza/600 mg jednokratna doza)
Ethanol/Dolutegravir
etanol/dolutegravir
Ethanol: the metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%.
Etanol: Metabolizam abakavira se mijenja istovremenim uzimanjem etanola, što dovodi do povećanja AUC-a abakavira za oko 41%.
Ether of fatty alcohols and of polyols Triethanolamine
Polioksietilenske masne kiseline Eter masnih kiselina i poliola Trietanolamin
ethindrone
(tableta koja
ethindrone
noretindron
ethinyl
1,26
Ethinyl estradiol
Etinil estradiol
Ethinyl estradiol
Etiniles- tradiol
Ethinyl estradiol
Etinilestradiol
Ethinyl estradiol (EE)
etinilestradiol (EE) i
Ethinyl estradiol (EE) and Norgestromin (NGMN)/Dolutegravir
etinilestradiol (EE) i norelgestromin (NGMN)/dolutegravir
Ethinyl estradiol (saquinavir/ritonavir)
Etinilestradiol (sakvinavir/ritonavir)
Ethinyl estradiol (saquinavir/ritonavir)
Ranitidin (nepojačani sakvinavir)
Ethinyl estradiol 0.035
Etinil estradiol 0,035
ethinyl estradiol and at
adrži etinilestradiol i najmanje
ethinyl estradiol AUC ↓ 24%
etinilestradiol AUC ↓ 24
ethinyl estradiol AUC ↓ 26%
etinilestradiol AUC ↓ 26
Ethinyl Estradiol AUC  2 % Ethinyl Estradiol Cmax ↑ 6 % Norelgestromin AUC ↑ 14 % Norelgestromin Cmax ↑ 29 %
etinil estradiol AUC  2% etinil estradiol Cmax ↑ 6% norelgestromin AUC ↑ 14% norelgestromin Cmax ↑ 29
ethinyl estradiol Cmax ↓ 21%
etinilestradiol Cmax ↓ 21
ethinyl estradiol Cmax ↔
etinilestradiol Cmax ↔
Ethinyl Estradiol Norelgestromin (raltegravir 400 mg Twice Daily)
etinil estradiol norelgestromin (raltegravir 400 mg dvaput na dan)
Ethinyl Estradiol Norelgestromin /lamivudine
etinil estradiol norelgestromin/lamivudin
Ethinyl Estradiol Norelgestromin /raltegravir (raltegravir 400 mg Twice Daily)
etinil estradiol norelgestromin/raltegravir (raltegravir 400 mg dvaput na dan)
Ethinyl estradiol: Cmax
Etinil estradiol: Cmax 28
Ethinyl Oestradiol
Etinilestradiol
Ethinyl oestradiol (EE) / Levonorgestrel (LNG)
Etinilestradiol (EE) /levonorgestrel (LNG)
Ethinyl oestradiol and norenthrindone (CYP3A4/5 substrates)
Etinilestradiol i noretindron (supstrati za CYP3A4/5)
Ethinyl oestradiol and norenthrindone: no dose adjustment required.
Etinilestradiol i noretindron: nije potrebna prilagodba doze.
Ethinyl oestradiol:
Famciklovir/emtricitabin
Ethinyl oestradiol: AUC: ↔
Etinilestradiol: AUC: ↔
Ethinyl Oestradiol: ↓
AUC: ↓ 45
Ethinylestrad-
etinilestra
ethinylestradi
Ctrough
ethinylestradiol
etinilestra
ethinylestradiol
etinilestradiol
Ethinylestradiol (0.025 mg once
Etinilestradiol (0,025 mg jedanput
Ethinylestradiol (0.035 mg once daily)/ Rilpivirine
Etinilestradiol (0,035 mg jedanput na dan)/rilpivirin
Ethinylestradiol 35 μg once daily for 21 days + norgestimate 0.180/0.215/0.250 mg once daily for 7/7/7 days (daclatasvir 60 mg once daily)
etinilestradiol 35 μg jedanput na dan tijekom 21 dana + norgestimat 0,180/0,215/0,250 mg jedanput na dan tijekom 7/7/7 dana (daklatazvir 60 mg jedanput na dan)
Ethinylestradiol and
Metadon7
Ethinylestradiol and terbutaline
Etinilestradio-l i terbutalin
ethinylestradiol AUC 1.12 (1.05-1.20) ↔
R(-) metadon AUC 0,99 (0,91-1,09) ↔
ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindrone AUC ↓ 14% norethindrone Cmin ↓ 30% norethindrone Cmax ↔
etinilestradiol Cmin ↓ 62% etinilestradiol Cmax ↓ 32% noretindron AUC ↓ 14% noretindron Cmin ↓ 30
ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindrone AUC ↓ 14% norethindrone Cmin ↓ 30% norethindrone Cmax ↔
etinilestradiol Cmin ↓ 62% etinilestradiol Cmax ↓ 32% noretindron AUC ↓ 14% noretindron Cmin ↓ 30% noretindron Cmax ↔
ethinylestradiol AUC ↔ ethinylestradiol Cmin ↔ ethinylestradiol Cmax ↑ 17% norethindrone AUC ↔ norethindrone Cmin ↔ norethindrone Cmax ↔ rilpivirine AUC ↔* rilpivirine Cmin ↔* rilpivirine Cmax ↔*
etinilestradiol AUC ↔ etinilestradiol Cmin ↔ etinilestradiol Cmax ↑ 17% noretindron AUC ↔ noretindron Cmin ↔ noretindron Cmax ↔ rilpivirin AUC ↔* rilpivirin Cmin ↔* rilpivirin Cmax ↔
Ethinylestradiol AUC: 1.01 (0.95, 1.07)
NARKOTIČKI ANALGETICI
Ethinylestradiol Cmax  36% Ethinylestradiol AUCτ  61% Norethisterone Cmax  15% Norethisterone AUCτ  53% Voriconazole Cmax  14% Voriconazole AUCτ  46%
Etinilestradiol Cmax  36% Etinilestradiol AUC  61% Noretisteron Cmax  15% Noretisteron AUC  53% Vorikonazol Cmax  14% Vorikonazol AUC  46
Ethinylestradiol Cmax  36% Ethinylestradiol AUC  61% Norethisterone Cmax  15% Norethisterone AUC  53% Voriconazole Cmax  14% Voriconazole AUC  46%
Etinilestradiol Cmax  36% Etinilestradiol AUC  61% Noretisteron Cmax  15% Noretisteron AUC  53% Vorikonazol Cmax  14% Vorikonazol AUC  46
ethinylestradiol Cmin 1.00 (0.89-1.13) ↔
R(-)metadon Cmin 1,02 (0,93-1,12) ↔
ethinylestradiol containing medicines such as those contained in most contraceptive pills and vaginal rings used for contraception
lijekovi koji sadrže etinilestradiol, poput većine lijekova za sprječavanje začeća i vaginalni kontracepcijski prstenovi.
Ethinylestradiol Norethindrone
8/2 mg–16/4 mg
Ethinylestradiol Norethindrone
Noretindron
ethinylestradiol*
etinilestradiol
Ethinylestradiol-containing
Oralni kontraceptivi koji
ethinylestradiol-containing medicines such as those contained in most contraceptive pills and vaginal rings used for contraception
lijekovi koji sadrže etinilestradiol koji se nalazi u većini kontracepcijskih tableta i vaginalnim prstenovima koji se koriste za kontracepciju
Ethinylestradiol/Norethindrone/ Emtricitabine
Etinilestradiol/noretindron/ emtricitabin
Ethinylestradiol:
Etinilestradiol:
Ethinylestradiol: AUC: ↓ 25%
Etinilestradiol: AUC: ↓ 25
Ethinyloestradiol + norgestimate / efavirenz (0.035 mg + 0.25 mg once daily/600 mg once daily)
Etiniloestradiol + norgestimat /
Ethinyloestradiol + Norgestimate/ Efavirenz (0.035 mg + 0.25 mg once daily/600 mg once daily)
etinilestradiol + norgestimat / efavirenz (0,035 mg + 0,25 mg jedanput na dan/600 mg jedanput na dan)
Ethinyloestradiol 25 μg +
Etinilestradiol 25 μg +
Ethinyloestradiol 35 µg +
Etinilestradiol 35 μg +
Ethinyloestradiol AUC ↑48% (↑31%
Etinilestradiol AUC ↑48% (↑31
Ethinyloestradiol AUC ↓19% (↓25%
Etinilestradiol AUC ↓19% (↓25
Ethinyloestradiol Cmax ↓16% (↓26%
Etinilestradiol Cmax ↓16% (↓26% ↓5%)
Ethinyloestradiol Cmin ↑91% (↑57%
Etinilestradiol Cmin ↑91% (↑57
Ethinyloestradiol Cmin ↓37% (↓45%
Etinilestradiol Cmin ↓37% (↓45
ethinyloestradiol levels because of the
razina etinilestradiola zbog
Ethinyloestradiol/Tenofovir disoproxil fumarate (-/300 mg q.d.)
etinilestradiol/tenofovirdizoproksil fumarat (-/300 mg q.d.)
Ethinyloestradiol: AUC: +--
etinilestradiol: AUC: ↔
Ethinyloestradiol: AUC: ↔
etinilestradiol: AUC: ↔
Ethinyloestradiol: AUC: ↔
pouzdana mehanička metoda
Ethnic factors.
Faktori etničke pripadnosti.
Ethnic group
Etnička skupina
Ethnic groups
Etničke skupine
Ethnic orgin (DVT/PE treatment)
Etničko porijeklo (liječenje DVT/PE-a)
Ethnic origin (DVT/PE prevention)
Etničko porijeklo (prevencija DVT/PE-a)
Ethnic origin (SPAF)
Etničko porijeklo (prevencija MU i SE kod AF)
Ethnic origin:
Etničko podrijetlo:
Ethnic populations
Etničke populacije
Ethnicity
Rasa
Ethnicity
Rasna pripadnost
Ethnicity: In clinical pharmacology studies, after adjusting for body weight, the AUC of the active metabolite was approximately 19% higher in Chinese, Japanese, and Korean subjects compared to that of Caucasians, predominantly related to higher exposure in Asian subjects < 60 kg.
Etničko podrijetlo: U kliničkim farmakološkim ispitivanjima je nakon korekcije za tjelesnu težinu AUC aktivnog metabolita bio približno 19% veći u ispitanika kineskog, japanskog i korejskog podrijetla nego u bijelaca, što je uglavnom bilo povezano s većom izloženošću u Azijata tjelesne težine <60 kg.
Ethnicity: In clinical pharmacology studies, after adjusting for body weight, the AUC of the active metabolite was approximately 19% higher in Chinese, Japanese, and Korean subjects compared to that of Caucasians, predominantly related to higher exposure in Asian subjects < 60 kg.
Etničko podrijetlo: U kliničkim farmakološkim ispitivanjima je nakon korekcije za tjelesnu težinu AUC aktivnog metabolita bio približno 19% veći u ispitanika kineskog, japanskog i korejskog podrijetla nego u bijelaca, što je uglavnom bilo povezano s većom izloženošću u Azijata tjelesne težine< 60 kg.
Ethyl alcohol Glycerol Sodium chloride
Etilni alkohol Glicerol Natrij klorid
Ethylen-vinyl-acetate cryo bag (EVA)
Krio vrećica od etilen vinil acetat (EVA)
Ethylene/maleic anhydride (EMA-31) Neocryl
Etilen/Anhidrid maleinske kiseline (EMA) Neocryl A640
Ethylene/maleic anhydride (EMA-31) Neocryl
Etilen/Anhidrid maleinske kiseline (EMA-31) Neocryl A640
Etonogestrel/Tenofovir disoproxil fumarate
etonogestrel/tenofovirdizoproksil fumarat
Etoposide 250 mg/ m2 i.v. (1 h) days 4-5;
Etopozid 250 mg/m2 i.v. (1 h) dani 4-5;